Table 1

Selected migraine drug development programs (compiled from http://www.clinicaltrials.gov webcite).

Drug

Mechanism of action

Stage of development


Acute attack


Telcagepant (MK-0974)

CGRP receptor antagonist

Phase III- complete


BI 44370

CGRP receptor antagonist

Phase II


COL-144

5-HT1F receptor agonists

Phase II


SB-705498

TRPV1 receptor antagonists

Phase II


BGG492

AMPA receptor antagonist

Phase II


Tezampanel (LY-293558)

AMPA and kainate receptor antagonist

Phase II


LY466195

GLUK5 kainate receptor antagonists

Phase II


NPS 1776

Anticonvulsant

Phase II


BGC20-1531

Prostanoid EP4 receptor antagonist

Phase II


NXN-188

nNOS inhibition and 5-HT1B/D agonist

Phase II


Preventives


Ramelteon

Melatonin MT1 and MT2 receptor agonist

Phase IV


Botulinum Toxin type A

Unknown

Phase III


Tonabersat

Gap junction/CSD inhibitor

Phase II- failed in migraine without aura


ADX10059

mGluR5 Modulator

Phase II


Perampanel (E2007)

AMPA receptor antagonist

Phase II


GW274150

iNOS

Phase II- failed


Carisbamate (RWJ-333369)

Anticonvulsant

Phase II- failed


CGRP, calcitonin gene-related peptide; CSD, cortical spreading depression; nNOS, nitric oxide synthase; iNOS, inducible nitric oxide synthase

Sprenger and Goadsby BMC Medicine 2009 7:71   doi:10.1186/1741-7015-7-71

Open Data